{"abstract":"The National Center for Advancing Translational Sciences, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the SUPPLEMENTARY INFORMATION section of this Notice to Elgia Therapeutics Inc. (\"Elgia\"), headquartered in La Jolla, CA.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2023/07/21/2023-15445.html","cfr_references":[],"citation":"88 FR 47152","comment_url":null,"comments_close_on":"2023-08-07","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the National Center for Advancing Translational Sciences' Office of Strategic Alliances on or before August 7, 2023 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2023-15445","effective_on":null,"end_page":47153,"executive_order_notes":null,"executive_order_number":null,"explanation":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2023/07/21/2023-15445.xml","html_url":"https://www.federalregister.gov/documents/2023/07/21/2023-15445/prospective-grant-of-an-exclusive-patent-license-development-and-commercialization-of-caspase","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2023-15445?publication_date=2023-07-21","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2023-07-21/2023-15445/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":137,"last_updated":"2026-04-05 06:15:03 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2023-07-21/pdf/2023-15445.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2023-15445.pdf?1689857121","publication_date":"2023-07-21","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2023/07/21/2023-15445.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-07-21T08:06:33Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":47152,"subtype":null,"title":"Prospective Grant of an Exclusive Patent License: Development and Commercialization of Caspase Inhibitors","toc_doc":"Development and commercialization of Caspase Inhibitors","toc_subject":"Prospective Grant of an Exclusive Patent License:\n","topics":[],"type":"Notice","volume":88}